Deqi Pharmaceutical is a leading biopharmaceutical company focused on innovative antineoplastic drugs. Our uniqueness comes from our industry-leading R & D capabilities and differentiated strategic approaches to developing new antineoplastic therapies. Our vision is to discover, develop and commercialize the world's first, unique and / or best-of-class therapy, treat patients without borders and improve their living standards.
Through the effective use of resources, outstanding ability in target selection and differentiated R & D strategy, Deqi Pharmaceuticals has established a strong and highly coordinated R & D pipeline of 12 products, including two late clinical assets and four early clinical assets. In addition, we are developing six pre-clinical R & D drugs that focus on innovative targets or mechanisms and have the potential to be number one in their class to address huge unmet medical needs. Moreover, these drugs target the key pathways of carcinogenesis and have the potential to be combined with each other.
Since its inception, we have established a solid R & D framework in the Asia-Pacific region and have a pan-Asia-Pacific clinical R & D capability. At this stage, we are establishing a commercialization team in the Asia-Pacific region to support the recent product launch, which is made up of multinational leaders with rich business experience and experienced practitioners who have in-depth knowledge of the developments in each local market.
CEO： Jianming Mei
Market： Hong Kong motherboard
Listing Date： 11/20/2020